Our data suggest that counteracting PDPN expression in activated CAFs or treating them with a TGF-β receptor inhibitor or a ROCK inhibitor, reduces their ability to support colon adenocarcinoma cell growth. The gene discussed is PDPN; the disease is colon adenocarcinoma.